Assay for the Pancreatic Polypeptide: an Help for Clinical Practice Guidelines in Classification of the Diabetes
NCT ID: NCT03396146
Last Updated: 2026-01-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
36 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-06-14
Study Completion Date
2019-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate global endocrine function within type 1 and type 3c diabetic patients, helping pancreatic polypeptide measurement.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Small Intestinal Endocrine Cells in Type 2 Diabetic Hyperglucagonemia
NCT00639613
Type 2 Diabetes
COMPLETED
Separate and Combined Extrapancreatic Effects of the Incretin Hormones
NCT05177653
Pancreatectomy; Hyperglycemia
COMPLETED
NA
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
NCT00732602
Diabetes Mellitus
COMPLETED
NA
The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes
NCT03734718
Diabetes Mellitus, Type 1
Hypoglycemia
COMPLETED
NA
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
NCT03556098
Diabetes Mellitus, Type 1
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All diabetes are the result of endrocrine deficiency. The endocrine deficiency may be absolute, as in type 1 diabetes, considered as an elective and exclusive attack of pancreatic Beta cell, or it could be relative, as un type 2 diabetes.
More rarely, diabetes fit into a broader context of pancreatic failure, with diffuse involvement of the exocrine and endocrine function, suggesting an impairment of the whole endocrine secretion of the pancreas, affecting the entire islet of Langerhans, such as in type 3c diabetes, whose prototypes are total pancreatectomy, chronic alcoholic pancreatitis, cystic fibrosis.
The diagnostic of type 3c diabetes is not always obvious, with several clinical presentations, without biological specific disease tag. Moreover, it also appears that the common form of diabetes, type 1 and type 2, may be associated with an exocrine function deficit and with a decrease of the pancreatic volume correlated with exocrine function abnormalities, and a decrease of insulin secretion capacity. The consequences of a spread of the disease beyond the Beta cells remain uncertain, but they could be linked, as in type 3c diabetes, with severe form of hypoglycaemia, due to glucagon deficiency, or nutritional deficiency due to the exocrine deficiency.
The pancreatic polypeptide belongs to the neuropeptide Y family, it is produced by the endocrine pancreatic F cells, located in the hook and the head of the pancreas. Food intake stimulates its secretion. The role of the pancreatic polypeptide in human is uncertain.
Investigators propose to study the pancreatic polypeptide in type 1 and type 3c diabetes before and after a mixed meal in order to study the other endocrine functions of the islet of Langerhans, to evaluate the possibility, or not, of a more diffuse pancreatic involvement in type 1 diabetes, considered as an elective pathology of the pancreatic Beta cell.
More rarely, diabetes fit into a broader context of pancreatic failure, with diffuse involvement of the exocrine and endocrine function, suggesting an impairment of the whole endocrine secretion of the pancreas, affecting the entire islet of Langerhans, such as in type 3c diabetes, whose prototypes are total pancreatectomy, chronic alcoholic pancreatitis, cystic fibrosis.
The diagnostic of type 3c diabetes is not always obvious, with several clinical presentations, without biological specific disease tag. Moreover, it also appears that the common form of diabetes, type 1 and type 2, may be associated with an exocrine function deficit and with a decrease of the pancreatic volume correlated with exocrine function abnormalities, and a decrease of insulin secretion capacity. The consequences of a spread of the disease beyond the Beta cells remain uncertain, but they could be linked, as in type 3c diabetes, with severe form of hypoglycaemia, due to glucagon deficiency, or nutritional deficiency due to the exocrine deficiency.
The pancreatic polypeptide belongs to the neuropeptide Y family, it is produced by the endocrine pancreatic F cells, located in the hook and the head of the pancreas. Food intake stimulates its secretion. The role of the pancreatic polypeptide in human is uncertain.
Investigators propose to study the pancreatic polypeptide in type 1 and type 3c diabetes before and after a mixed meal in order to study the other endocrine functions of the islet of Langerhans, to evaluate the possibility, or not, of a more diffuse pancreatic involvement in type 1 diabetes, considered as an elective pathology of the pancreatic Beta cell.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type1diabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Type1diabetes with exocrine pancreatic function insufficiency
12 ml total blood tubes volume Fecal sample
Group Type
EXPERIMENTAL
12 ml total blood tubes volume
Intervention Type
OTHER
12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
Fecal sample
Intervention Type
OTHER
Fecal sample at inclusion
Type1diabetes without exocrine pancreatic function insuficienc
12 ml total blood tubes volume Fecal sample
Group Type
EXPERIMENTAL
12 ml total blood tubes volume
Intervention Type
OTHER
12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
Fecal sample
Intervention Type
OTHER
Fecal sample at inclusion
Type 3c diabetes
12 ml total blood tubes volume Fecal sample
Group Type
ACTIVE_COMPARATOR
12 ml total blood tubes volume
Intervention Type
OTHER
12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
Fecal sample
Intervention Type
OTHER
Fecal sample at inclusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
12 ml total blood tubes volume
12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
Intervention Type
OTHER
Fecal sample
Fecal sample at inclusion
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged 18 years or older
* Patients with type 1 diabetes with anti-GAD and / or IA2 and / or Znt8 positive antibodies, or characteristic clinical history, with and without exocrine deficiency (\*)
* Patients with chronic alcoholic pancreatitis or cystic fibrosis origin (type 3c diabetes), complicated with diabetes defined by HbA1c\> 6.5% or treated with oral anti-diabetic and / or insulin
* Patients who have given informed and written consent to participate in research
* Patients affiliated to a social security scheme (\*): The exocrine deficiency is defined by an assay of fecal elastase:
* without deficit of exocrine function = fecal elastase = /\> 100 μg / g
* with deficit of exocrine function = fecal elastase \<100 μg / g
* Patients with type 1 diabetes with anti-GAD and / or IA2 and / or Znt8 positive antibodies, or characteristic clinical history, with and without exocrine deficiency (\*)
* Patients with chronic alcoholic pancreatitis or cystic fibrosis origin (type 3c diabetes), complicated with diabetes defined by HbA1c\> 6.5% or treated with oral anti-diabetic and / or insulin
* Patients who have given informed and written consent to participate in research
* Patients affiliated to a social security scheme (\*): The exocrine deficiency is defined by an assay of fecal elastase:
* without deficit of exocrine function = fecal elastase = /\> 100 μg / g
* with deficit of exocrine function = fecal elastase \<100 μg / g
Exclusion Criteria
* Pregnancy
* Severe renal impairment (eDFG \<45 mL / min / 1.73 m²)
* Severe renal impairment (eDFG \<45 mL / min / 1.73 m²)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cochin Hospital's Hormonology Laboratory
UNKNOWN
Sponsor Role
collaborator
URC-CIC Paris Descartes Necker Cochin
OTHER
Sponsor Role
collaborator
Assistance Publique - Hôpitaux de Paris
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Etienne LARGER, MD, PhD
Role: STUDY_CHAIR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cochin Hospital
Paris, Paris, France
Site Status
Countries
Review the countries where the study has at least one active or historical site.
France
References
Explore related publications, articles, or registry entries linked to this study.
Haldorsen IS, Raeder H, Vesterhus M, Molven A, Njolstad PR. The role of pancreatic imaging in monogenic diabetes mellitus. Nat Rev Endocrinol. 2011 Nov 29;8(3):148-59. doi: 10.1038/nrendo.2011.197.
Reference Type
BACKGROUND
Larger E, Philippe MF, Barbot-Trystram L, Radu A, Rotariu M, Nobecourt E, Boitard C. Pancreatic exocrine function in patients with diabetes. Diabet Med. 2012 Aug;29(8):1047-54. doi: 10.1111/j.1464-5491.2012.03597.x.
Reference Type
BACKGROUND
Philippe MF, Benabadji S, Barbot-Trystram L, Vadrot D, Boitard C, Larger E. Pancreatic volume and endocrine and exocrine functions in patients with diabetes. Pancreas. 2011 Apr;40(3):359-63. doi: 10.1097/MPA.0b013e3182072032.
Reference Type
BACKGROUND
Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST, Brand R, Frulloni L, Anderson MA, Whitcomb DC; PancreasFest Recommendation Conference Participants. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology. 2013 Jul-Aug;13(4):336-42. doi: 10.1016/j.pan.2013.05.002. Epub 2013 May 17.
Reference Type
BACKGROUND
Khandekar N, Berning BA, Sainsbury A, Lin S. The role of pancreatic polypeptide in the regulation of energy homeostasis. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:33-41. doi: 10.1016/j.mce.2015.06.028. Epub 2015 Jun 27.
Reference Type
BACKGROUND
Hennig R, Kekis PB, Friess H, Adrian TE, Buchler MW. Pancreatic polypeptide in pancreatitis. Peptides. 2002 Feb;23(2):331-8. doi: 10.1016/s0196-9781(01)00605-2.
Reference Type
BACKGROUND
Wang X, Zielinski MC, Misawa R, Wen P, Wang TY, Wang CZ, Witkowski P, Hara M. Quantitative analysis of pancreatic polypeptide cell distribution in the human pancreas. PLoS One. 2013;8(1):e55501. doi: 10.1371/journal.pone.0055501. Epub 2013 Jan 31.
Reference Type
BACKGROUND
Simonian HP, Kresge KM, Boden GH, Parkman HP. Differential effects of sham feeding and meal ingestion on ghrelin and pancreatic polypeptide levels: evidence for vagal efferent stimulation mediating ghrelin release. Neurogastroenterol Motil. 2005 Jun;17(3):348-54. doi: 10.1111/j.1365-2982.2004.00634.x.
Reference Type
BACKGROUND
Veedfald S, Plamboeck A, Hartmann B, Svendsen LB, Vilsboll T, Knop FK, Holst JJ. Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. Peptides. 2015 Sep;71:229-31. doi: 10.1016/j.peptides.2015.07.020. Epub 2015 Jul 26.
Reference Type
BACKGROUND
Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003 Aug;88(8):3989-92. doi: 10.1210/jc.2003-030630.
Reference Type
BACKGROUND
Brunicardi FC, Chaiken RL, Ryan AS, Seymour NE, Hoffmann JA, Lebovitz HE, Chance RE, Gingerich RL, Andersen DK, Elahi D. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab. 1996 Oct;81(10):3566-72. doi: 10.1210/jcem.81.10.8855802.
Reference Type
BACKGROUND
Rabiee A, Galiatsatos P, Salas-Carrillo R, Thompson MJ, Andersen DK, Elahi D. Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy. J Diabetes Sci Technol. 2011 Nov 1;5(6):1521-8. doi: 10.1177/193229681100500629.
Reference Type
BACKGROUND
Henquin JC, Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia. 2011 Jul;54(7):1720-5. doi: 10.1007/s00125-011-2118-4. Epub 2011 Apr 5.
Reference Type
BACKGROUND
Diedisheim M, Mallone R, Boitard C, Larger E. beta-cell Mass in Nondiabetic Autoantibody-Positive Subjects: An Analysis Based on the Network for Pancreatic Organ Donors Database. J Clin Endocrinol Metab. 2016 Apr;101(4):1390-7. doi: 10.1210/jc.2015-3756. Epub 2016 Feb 1.
Reference Type
BACKGROUND
Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science. 1973 Oct 12;182(4108):171-3. doi: 10.1126/science.182.4108.171.
Reference Type
BACKGROUND
Lund A, Bagger JI, Wewer Albrechtsen NJ, Christensen M, Grondahl M, Hartmann B, Mathiesen ER, Hansen CP, Storkholm JH, van Hall G, Rehfeld JF, Hornburg D, Meissner F, Mann M, Larsen S, Holst JJ, Vilsboll T, Knop FK. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes. 2016 Mar;65(3):585-97. doi: 10.2337/db15-1541. Epub 2015 Dec 15.
Reference Type
BACKGROUND
Tiengo A, Bessioud M, Valverde I, Tabbi-Anneni A, Delprato S, Alexandre J, Assan R. Absence of islet alpha cell function in pancreatectomized patients. Diabetologia. 1982 Jan;22(1):25-32. doi: 10.1007/BF00253865.
Reference Type
BACKGROUND
Bellanne-Chantelot C, Chauveau D, Gautier JF, Dubois-Laforgue D, Clauin S, Beaufils S, Wilhelm JM, Boitard C, Noel LH, Velho G, Timsit J. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med. 2004 Apr 6;140(7):510-7. doi: 10.7326/0003-4819-140-7-200404060-00009.
Reference Type
BACKGROUND
Andersen BN, Hagen C, Klein HC, Stadil F, Worning H. Correlation between exocrine pancreatic secretion and serum concentration of human pancreatic polypeptide in chronic pancreatitis. Scand J Gastroenterol. 1980;15(6):699-704. doi: 10.3109/00365528009181517.
Reference Type
BACKGROUND
Matsumoto M, Wakasugi H, Ibayashi H. Plasma human pancreatic polypeptide response in chronic pancreatitis. Gastroenterol Jpn. 1982;17(1):25-30. doi: 10.1007/BF02774757.
Reference Type
BACKGROUND
Vu MK, Vecht J, Eddes EH, Biemond I, Lamers CB, Masclee AA. Antroduodenal motility in chronic pancreatitis: are abnormalities related to exocrine insufficiency? Am J Physiol Gastrointest Liver Physiol. 2000 Mar;278(3):G458-66. doi: 10.1152/ajpgi.2000.278.3.G458.
Reference Type
BACKGROUND
Sobngwi E, Boudou P, Mauvais-Jarvis F, Leblanc H, Velho G, Vexiau P, Porcher R, Hadjadj S, Pratley R, Tataranni PA, Calvo F, Gautier JF. Effect of a diabetic environment in utero on predisposition to type 2 diabetes. Lancet. 2003 May 31;361(9372):1861-5. doi: 10.1016/S0140-6736(03)13505-2.
Reference Type
BACKGROUND
Chia CW, Odetunde JO, Kim W, Carlson OD, Ferrucci L, Egan JM. GIP contributes to islet trihormonal abnormalities in type 2 diabetes. J Clin Endocrinol Metab. 2014 Jul;99(7):2477-85. doi: 10.1210/jc.2013-3994. Epub 2014 Apr 8.
Reference Type
BACKGROUND
Belinova L, Kahleova H, Malinska H, Topolcan O, Vrzalova J, Oliyarnyk O, Kazdova L, Hill M, Pelikanova T. Differential acute postprandial effects of processed meat and isocaloric vegan meals on the gastrointestinal hormone response in subjects suffering from type 2 diabetes and healthy controls: a randomized crossover study. PLoS One. 2014 Sep 15;9(9):e107561. doi: 10.1371/journal.pone.0107561. eCollection 2014.
Reference Type
BACKGROUND
Hart PA, Baichoo E, Bi Y, Hinton A, Kudva YC, Chari ST. Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus. Pancreatology. 2015 Mar-Apr;15(2):162-6. doi: 10.1016/j.pan.2015.02.006. Epub 2015 Feb 24.
Reference Type
BACKGROUND
Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597-604. doi: 10.1056/NEJMoa1105816.
Reference Type
BACKGROUND
Nealon WH, Townsend CM Jr, Thompson JC. The time course of beta cell dysfunction in chronic ethanol-induced pancreatitis: a prospective analysis. Surgery. 1988 Dec;104(6):1074-9.
Reference Type
BACKGROUND
Brunicardi FC, Druck P, Sun YS, Elahi D, Gingerich RL, Andersen DK. Regulation of pancreatic polypeptide secretion in the isolated perfused human pancreas. Am J Surg. 1988 Jan;155(1):63-9. doi: 10.1016/s0002-9610(88)80259-9.
Reference Type
BACKGROUND
Dehghani L, Bonnet-Serrano F, Abdul H, Alexandre-Heymann L, Guibourdenche J, Larger E. Pancreatic polypeptide in patients with type 1 diabetes and exocrine failure or chronic pancreatitis. The DIAPP study. Diabetes Metab. 2025 Nov 9;52(1):101712. doi: 10.1016/j.diabet.2025.101712. Online ahead of print.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A00612-51
Identifier Type: REGISTRY
Identifier Source: secondary_id
K160403J
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines
NCT03241303
COMPLETED
NA
A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis
NCT07314489
RECRUITING
EARLY_PHASE1
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
NCT00655603
UNKNOWN
NA
The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus
NCT02413762
COMPLETED
Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages
NCT01916265
COMPLETED
PHASE1
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes
NCT06120556
COMPLETED
The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients
NCT00791076
TERMINATED
PHASE2
GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia
NCT00716170
COMPLETED
Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and Graded Intravenous Infusion
NCT03223129
COMPLETED
NA
Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus
NCT00603031
COMPLETED
NA
Incretin Hormones in Type-1 Diabetes Mellitus Glycemic Response in Type-1 Diabetes Mellitus
NCT00832741
COMPLETED
The Role of Oxytocin in Regulating Blood Glucose
NCT06334172
RECRUITING
NA
Study of Circulating Levels of Glicentin
NCT03671928
COMPLETED
NA
Effect of GIP After a Meal in Patients With Type 2 Diabetes
NCT03702660
COMPLETED
NA
Study of Postprandial Incretin Response in Women With Gestational Diabetes
NCT01274052
COMPLETED
Association of Kisspeptin Levels With Insulin Secretion in Diabetes Mellitus
NCT01956851
COMPLETED
Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?
NCT01048268
COMPLETED
PHASE1/PHASE2
Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes
NCT01747967
COMPLETED
NA
C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes
NCT04005261
COMPLETED
Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion
NCT02010827
COMPLETED
Hepatic Metabolic Changes in Response to Glucagon Infusion
NCT03526445
COMPLETED
NA
Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment
NCT04177303
UNKNOWN
PHASE3
Hyperglycemia and the Extra-pancreatic Effect of Incretins
NCT01749163
COMPLETED
NA
Glucolipotoxicity and Type 2 Diabetes
NCT01375270
COMPLETED
NA
Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat)
NCT06333132
NOT_YET_RECRUITING
NA